Suppr超能文献

胸内寡转移结节能否安全地采用图像引导低分割放射治疗?

Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?

机构信息

Radiotherapy and Radiosurgery Department, Humanitas Clinical and Research Center, Rozzano-Milano, Italy.

Department of Radiation Therapy, San Pietro Fatebenefratelli Hospital, Rome, Italy.

出版信息

Br J Radiol. 2019 Nov;92(1103):20181026. doi: 10.1259/bjr.20181026. Epub 2019 Sep 17.

Abstract

OBJECTIVE

To evaluate safety and efficacy of image guided-hypofractionated radiation therapy (IG-HRT) in patients with thoracic nodes oligometastases.

METHODS

The present study is a multicenter analysis. Oligometastatic patients, affected by a maximum of five active lesions in three or less different organs, treated with IG-HRT to thoracic nodes metastases between 2012 and 2017 were included in the analysis. Primary end point was local control (LC), secondary end points were overall survival (OS), progression-free survival, acute and late toxicity. Univariate and multivariate analysis were performed to identify possible prognostic factors for the survival end points.

RESULTS

76 patients were included in the analysis. Different RT dose and fractionation schedules were prescribed according to site, number, size of the lymph node(s) and to respect dose constraints for relevant organs at risk. Median biologically effective dose delivered was 75 Gy (interquartile range: 59-86 Gy). Treatment was optimal; one G1 acute toxicity and seven G1 late toxicities of any grade were recorded. Median follow-up time was 23.16 months. 16 patients (21.05%) had a local progression, while 52 patients progressed in distant sites (68.42 %).Median local relapse free survival was not reached, LC at 6, 12 and 24 months was 96.05% [confidence interval (CI) 88.2698.71%], 86.68% (CI 75.8692.87) and 68.21% (CI 51.8980.00%), respectively. Median OS was 28.3 months (interquartile range 16.147.2). Median progression-freesurvival was 9.2 months (interquartile range 4.117.93).At multivariate analysis, RT dose, colorectal histology, systemic therapies were correlated with LC. Performance status and the presence of metastatic sites other than the thoracic nodes were correlated with OS. Local response was a predictor of OS.

CONCLUSION

IG-HRT for thoracic nodes was safe and feasible. Higher RT doses were correlated to better LC and should be taken in consideration at least in patients with isolated nodal metastases and colorectal histology.

ADVANCES IN KNOWLEDGE

Radiotherapy is safe and effective treatment for thoracic nodes metastases, higher radiotherapy doses are correlated to better LC. Oligometastatic patients can receive IG-HRT also for thoracic nodes metastases.

摘要

目的

评估图像引导的低分割放射治疗(IG-HRT)在胸部淋巴结寡转移患者中的安全性和疗效。

方法

本研究为多中心分析。纳入 2012 年至 2017 年间接受 IG-HRT 治疗的最大 5 个活跃病变且分布于 3 个或更少不同器官的胸部淋巴结寡转移患者。主要终点为局部控制(LC),次要终点为总生存(OS)、无进展生存、急性和迟发性毒性。采用单因素和多因素分析确定与生存终点相关的可能预后因素。

结果

76 例患者纳入分析。根据部位、淋巴结数量和大小以及对相关危及器官剂量限制的要求,采用不同的 RT 剂量和分割方案。中位生物有效剂量为 75Gy(四分位距:59-86Gy)。治疗效果最佳;记录到 1 例 G1 级急性毒性和 7 例任何级别 G1 级迟发性毒性。中位随访时间为 23.16 个月。16 例(21.05%)出现局部进展,52 例(68.42%)出现远处部位进展。中位局部无复发生存未达到,6、12 和 24 个月时的 LC 分别为 96.05%(置信区间 88.26-98.71%)、86.68%(置信区间 75.86-92.87%)和 68.21%(置信区间 51.89-80.00%)。中位 OS 为 28.3 个月(四分位距 16.1-72.0)。中位无进展生存期为 9.2 个月(四分位距 4.1-17.9)。多因素分析显示,RT 剂量、结直肠癌组织学、全身治疗与 LC 相关。功能状态和除胸部淋巴结以外的转移部位与 OS 相关。局部反应是 OS 的预测因素。

结论

IG-HRT 治疗胸部淋巴结安全可行。较高的 RT 剂量与更好的 LC 相关,至少应考虑用于孤立性淋巴结转移和结直肠癌组织学的患者。

知识进展

胸部淋巴结放疗是安全有效的治疗方法,较高的放疗剂量与更好的 LC 相关。寡转移患者也可接受 IG-HRT 治疗胸部淋巴结转移。

相似文献

1
Can thoracic nodes oligometastases be safely treated with image guided hypofractionated radiation therapy?
Br J Radiol. 2019 Nov;92(1103):20181026. doi: 10.1259/bjr.20181026. Epub 2019 Sep 17.
2
Oligometastases in prostate cancer : Metabolic response in follow-up PSMA-PET-CTs after hypofractionated IGRT.
Strahlenther Onkol. 2018 Apr;194(4):318-324. doi: 10.1007/s00066-017-1239-1. Epub 2017 Nov 27.
3
Prospective phase II trial on ablative stereotactic body radiation therapy (SBRT) for medically inoperable thoracic nodes metastases.
Radiother Oncol. 2024 Aug;197:110335. doi: 10.1016/j.radonc.2024.110335. Epub 2024 May 19.
4
Stereotactic Body Radiation Therapy for Mediastinal and Hilar Lymph Node Metastases.
Int J Radiat Oncol Biol Phys. 2021 Mar 1;109(3):764-774. doi: 10.1016/j.ijrobp.2020.10.004. Epub 2020 Oct 25.
9
Curative-intent radiotherapy in patients with oligometastatic lesions from colorectal cancer: A single-center study.
Medicine (Baltimore). 2018 Oct;97(40):e12601. doi: 10.1097/MD.0000000000012601.
10
Stereotactic radiation therapy for oligometastases or oligorecurrence within mediastinal lymph nodes.
Oncotarget. 2016 Apr 5;7(14):18135-45. doi: 10.18632/oncotarget.7636.

引用本文的文献

2
Developments in radiation techniques for thoracic malignancies.
Eur Respir Rev. 2021 May 5;30(160). doi: 10.1183/16000617.0224-2020. Print 2021 Jun 30.

本文引用的文献

2
Stereotactic Ablative Radiation Therapy for Pulmonary Metastases: Histology, Dose, and Indication Matter.
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):419-427. doi: 10.1016/j.ijrobp.2017.02.093. Epub 2017 Feb 28.
3
Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours.
J Cancer Res Clin Oncol. 2017 Jul;143(7):1293-1299. doi: 10.1007/s00432-017-2373-y. Epub 2017 Mar 3.
5
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Ann Oncol. 2016 Aug;27(8):1386-422. doi: 10.1093/annonc/mdw235. Epub 2016 Jul 5.
8
Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences.
Clin Oncol (R Coll Radiol). 2016 Sep;28(9):e115-20. doi: 10.1016/j.clon.2016.04.040. Epub 2016 Apr 28.
10
Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis.
Int J Radiat Oncol Biol Phys. 2015 Jan 1;91(1):124-32. doi: 10.1016/j.ijrobp.2014.08.345. Epub 2014 Oct 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验